AI A.I CyberSecurity Scoring
18/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for AbbVie | Immunology in 2026.
No incidents recorded for AbbVie | Immunology in 2026.
No incidents recorded for AbbVie | Immunology in 2026.
A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.
Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.
Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.
We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint
Latest updates, reports, and threat intel affecting the global network.
Scope of work: Collier oversees technology operations for the $5.3 billion system. Since joining in July 2024, he's led efforts to modernize infrastructure,...
Cyber immunity is not a product you install. It is a practical approach to online security, built on simple habits supported by technology.
Many SMEs think they're too small to be targeted, but the NCSC warns that attackers exploit weaknesses, and size doesn't protect against...
As the cybersecurity environment becomes more complex, Cyber Immunity is emerging as a vital strategy.
The cybersecurity landscape is evolving rapidly, with organisations seeking more robust ways to protect their digital assets.
The cybersecurity landscape in Egypt is evolving rapidly, with organizations seeking more robust ways to protect their digital assets.
If cybersecurity guards digital gold, artificial intelligence refines it. AI transforms raw data into actionable insights,...
Explore the five cybersecurity frontiers shaping 2050 — from digital immunity to deepfake wars — where protecting truth becomes the new...
Kaspersky's recent telemetry shows a 21 per cent rise in password stealers and 34 per cent increase in spyware across the GCC.
Authentication bypass using an alternate path or channel vulnerability in N-able N-central allows Authentication Bypass. This issue affects N-central: through 2026.1.
Improper Verification of Cryptographic Signature in ueberauth guardian allows an unauthenticated attacker to revoke a victim's session with a forged token. Guardian.revoke/3 in lib/guardian.ex decodes the supplied token with peek/1, which performs no signature verification (it only base64-decodes the JWT header and payload). The resulting unverified claims are forwarded directly to the configured token module's revoke callback and the implementation's on_revoke callback, a state-mutating sink. The sibling operations refresh/2 and exchange/4 both call decode_and_verify first, so the signature is checked before anything acts on the claims; revoke/3 is the only state-mutating path that acts on claims without verifying the signature. An attacker who knows or guesses a victim's identifying claim values (jti, sub) can forge a JWT carrying those claims, sign it with an arbitrary key, and submit it to any endpoint that funnels a caller-supplied token into Guardian.revoke/3 (the standard logout / session-revocation pattern). When the token module mutates state keyed by the claims (whitelist deletion or blacklist insertion, for example a GuardianDb-style store), the victim's legitimate session is evicted. This is an unauthenticated session-revocation denial of service; the attacker never needs the signing secret. This issue affects guardian: from 1.0.0 before 2.4.1.
Allocation of Resources Without Limits or Throttling vulnerability in ueberauth guardian (Guardian.Permissions module) allows a denial of service via BEAM atom-table exhaustion. This vulnerability is associated with program file lib/guardian/permissions.ex and program routines 'Elixir.Guardian.Permissions':encode_permissions!/1, 'Elixir.Guardian.Permissions':encode_permissions_into_claims!/2, 'Elixir.Guardian.Permissions':do_encode_permissions!/2. The Guardian.Permissions mixin installs a public encode_permissions!/1 function on every module that does use Guardian.Permissions. For each key of the supplied map, encode_permissions!/1 calls String.to_atom(to_string(k)) before any validation runs. The integer-value clause of do_encode_permissions!/2 then short-circuits straight to encoding without validating the key against the configured permission set, so a key with an integer value is interned as a fresh atom with no exception raised. Atoms are never garbage collected and the BEAM atom table is a fixed-size resource (default roughly 1,048,576 entries), so each unique attacker-chosen key permanently consumes one slot. An attacker who can influence a permission map that reaches encode_permissions!/1 (for example a permissions map read from a request body and passed into token issuance via encode_permissions_into_claims!/2) can mint an unbounded number of atoms and exhaust the atom table, crashing the entire BEAM node and every service running on it. The sibling decode_permissions/1 is not affected because it skips keys absent from the configured permission set. This issue affects guardian: from 2.0.0 before 2.4.1.
Allocation of Resources Without Limits or Throttling in ueberauth guardian allows denial of service via unbounded atom creation from attacker-controlled binary input. Guardian.Permissions.AtomEncoding encodes permission scopes by passing arbitrary binaries to String.to_atom/1. When encode/3 in lib/guardian/permissions/atom_encoding.ex is called with a list, each binary entry is handled by the encode_value/3 binary clause, which calls String.to_atom(value) with no allow-list check. The perm_set argument (the application's small, finite set of legitimate permission names) is discarded, so any external string flows straight into atom creation. This encoder is selected with use Guardian.Permissions, encoding: Guardian.Permissions.AtomEncoding and reached through the imported encode/3 entry point. String.to_atom/1 creates a brand-new atom for every previously unseen binary, atoms are never garbage collected, and the BEAM atom table is fixed at roughly 1,048,576 entries by default. An application that funnels attacker-influenced permission scopes (from a request body, a JWT claim, or other external input) into encode/3 therefore mints one permanent atom per distinct value. A modest stream of varied, unauthenticated input permanently consumes the atom table and crashes the BEAM node with system_limit, taking down every application running on it. The default encoder is Guardian.Permissions.BitwiseEncoding, which is not affected. This issue affects guardian: from 2.0.0 before 2.4.1.
Allocation of Resources Without Limits or Throttling in ueberauth guardian allows denial of service via unbounded atom creation from attacker-influenced binary input. Guardian.Plug.Keys derives connection and session namespace keys by passing arbitrary binaries to String.to_atom/1. base_key/1 in lib/guardian/plug/keys.ex converts any binary into the atom :"guardian_<input>", and the derived helpers claims_key/1, resource_key/1, and token_key/1 create a second atom on top of that. key_from_other/1 likewise converts a regex-captured binary through String.to_atom/1. The public specs advertise String.t() as a valid argument, so passing a string is documented usage, and higher-level entry points such as Guardian.Plug.current_token(conn, key: key) thread the caller-supplied key straight into these functions. String.to_atom/1 creates a brand-new atom for every previously unseen binary, atoms are never garbage collected, and the BEAM atom table is fixed at roughly 1,048,576 entries by default. An application that routes attacker-influenced data (a tenant identifier, header, or other request input) into a Guardian key therefore mints one permanent atom per distinct value. A modest stream of varied, unauthenticated input permanently consumes the atom table and crashes the BEAM node, taking down every application running on it. This issue affects guardian: from 0.1.0 before 2.4.1.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.